Metraipolis › archive › dc_222362913fb5

Zika Virus infection and Guillain-Barré syndrome in Northeastern Mexico: A case-control study — Europe PMC PMID:32214354

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/32214354
DOI
10.1371/journal.pone.0230132
License (as archived)
CC0-1.0
Archived
2026-11-09T03:13:22.423Z
SHA-256 of the archived text
d959521ce799b8661a8392b43948e26b856c180de1ea82f09cb2d5f88a7959d1
Stable URL of this page
https://metraipolis.com/documento/dc_222362913fb5

How to cite

Zika Virus infection and Guillain-Barré syndrome in Northeastern Mexico: A case-control study — Europe PMC PMID:32214354 — Europe PMC (en), https://europepmc.org/article/MED/32214354 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_222362913fb5 (Metraipolis archive dc_222362913fb5, sha256 d959521ce799b8661a8392b43948e26b856c180de1ea82f09cb2d5f88a7959d1)
BibTeX
@misc{dc222362913fb5,
  title = {Zika Virus infection and Guillain-Barré syndrome in Northeastern Mexico: A case-control study — Europe PMC PMID:32214354},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/32214354},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_222362913fb5; sha256 d959521ce799b8661a8392b43948e26b856c180de1ea82f09cb2d5f88a7959d1},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32214354. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Beginning August 2017, we conducted a prospective case-control investigation in Monterrey, Mexico to assess the association between Zika virus (ZIKV) and Guillain-Barré syndrome (GBS). Methods: For each of 50 GBS case-patients, we enrolled 2-3 afebrile controls (141 controls in total) matched by sex, age group, and presentation to same hospital within 7 days. Results: PCR results for ZIKV in blood and/or urine were available on all subjects; serum ZIKV IgM antibody for 52% of case-patients and 80% of controls. Subjects were asked about antecedent illness in the two months prior to neurological onset (for case-patients) or interview (for controls). Laboratory evidence of ZIKV infection alone (PCR+ or IgM+) was not significantly different between case-patients and controls (OR: 1.26, 95% CI: 0.45-3.54) but antecedent symptomatic ZIKV infection [a typical ZIKV symptom (rash, joint pain, or conjunctivitis) plus laboratory evidence of ZIKV infection] was higher among case-patients (OR: 12.45, 95% CI: 1.45-106.64). GBS case-patients with laboratory evidence of ZIKV infection were significantly more likely to have had typical ZIKV symptoms than controls with laboratory evidence of ZIKV infection (OR: 17.5, 95% CI: 3.2-96.6). This association remained significant even when only GBS case-patients who were afebrile for 5 days before onset were included in the analysis, (OR 9.57 (95% CI: 1.07 to 85.35). Conclusions: During ZIKV epidemics, this study indicates that increases in GBS will occur primarily among those with antecedent symptomatic ZIKV.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-03-26).
Identificativi: PMID 32214354 · PMCID PMC7098590 · DOI 10.1371/journal.pone.0230132.
Descrittori MeSH principali: Guillain-Barre Syndrome; Zika Virus; Zika Virus Infection.
Pagina: https://europepmc.org/article/MED/32214354 — https://doi.org/10.1371/journal.pone.0230132. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-09T03:05:56.513Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.